Watson Pharma (WPI) Receives FDA Approval for Generic Micro-K Extencaps
Up)
Watson Pharmaceuticals, Inc. (NYSE: WPI) received approval from the FDA of its Abbreviated New Drug Application for Potassium-Chloride Extended-Release Capsules USP in the 8mEq and 10mEq strengths.
Potassium-Chloride is the generic equivalent to KV Pharmaceutical's Micro-K Extencaps USP and is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis.
Potassium-Chloride is the generic equivalent to KV Pharmaceutical's Micro-K Extencaps USP and is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Rolling Out Another Assay
- NTRR Orders Initial Manufacturing Run of New pH Balance Formulas
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
